key: cord-0904867-pqfify35
authors: Dube, M.-P.; Lemacon, A.; Barhdadi, A.; Lemieux Perreault, L.-P.; Oussaid, E.; Asselin, G.; Provost, S.; Sun, M.; Sandoval, J.; Legault, M.-A.; Mongrain, I.; Dubois, A.; Valois, D.; Dedelis, E.; Lousky, J.; Choi, J.; Goulet, E.; Savard, C.; Chicoine, L.-M.; Cossette, M.; Chabot-Blanchet, M.; Guertin, M.-C.; de Denus, S.; Bouabdallaoui, N.; Marchand, R.; Bassevitch, Z.; Nozza, A.; Gaudet, D.; L'Allier, P. L.; Hussin, J.; Boivin, G.; Busseuil, D.; Tardif, J.-C.
title: Genetics of symptom remission in outpatients with COVID-19
date: 2021-03-01
journal: nan
DOI: 10.1101/2021.02.24.21252396
sha: 4b2e7cc76745843acbbcc24e4ffe2afea29c6625
doc_id: 904867
cord_uid: pqfify35

We conducted a genome-wide association study of time to remission of COVID-19 symptoms in 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial. We found a significant association at 5p13.3 (rs1173773; P = 4.94 x 10-8) near the natriuretic peptide receptor 3 gene (NPR3). By day 15 of the study, 44%, 54% and 59% of participants with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. In 851 participants not treated with colchicine (placebo), there was a significant association at 9q33.1 (rs62575331; P = 2.95 x 10-8) in interaction with colchicine (P = 1.19 x 10-5) without impact on risk of hospitalisations, highlighting a possibly shared mechanistic pathway. By day 15 of the study, 46%, 62% and 64% of those with 0, 1, or 2 copies of the effect allele respectively, had symptom remission. The findings need to be replicated and could contribute to the biological understanding of COVID-19 symptom remission.

The infectious disease syndrome known as coronavirus disease 2019 is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has become pandemic in 2020. Although most COVID-19 cases result in mild symptoms, some patients suffer severe symptoms, including severe pneumonia and multiorgan failure. There is also great variability in the duration of COVID-19 symptoms, with a majority of patients reporting remission of symptoms within 14 to 21 days in the outpatient setting, 1 while some patients experience prolonged multiorgan dysfunction and complications that last for 12 weeks or longer. 2 The study of host genetics can bring valuable support toward a better understanding of the mechanisms underlying COVID-19 and can guide the development of preventive and therapeutic measures to mitigate the health burden of this pandemic. Multiple efforts are underway to study the contribution of host genetics to COVID-19, with a focus on risk of severe COVID-19 outcomes and risk of infection with the SARS-CoV-2 virus. [3] [4] [5] [6] [7] In particular, one genetic locus, 3p21.31, has repeatedly been associated with severe respiratory illness and hospitalisation for reasons of COVID-19. 5, 7 However, few studies have focused on the genetics of symptoms duration and remission in outpatients. Persistence of COVID-19 symptoms is associated with a higher risk of complications, including prolonged hospitalization, and poor quality of life thereafter. 8 received a diagnosis of COVID-19 confirmed by a polymerase chain reaction (PCR) test, the primary endpoint occurred in 4.6% and 6.0% of patients in the colchicine and placebo groups respectively (OR 0.75; 95% CI, 0.57 to 0.99; P = 0.04). 9 Participants were invited to take part in an optional genetic substudy to this randomized clinical trial, which is presented here. We investigated the genetic predictors of time to remission of COVID-19 symptoms with the aim to gain a better understanding of disease progression in a recently diagnosed outpatient population.

COLCORONA was a randomised, double-blind, placebo-controlled trial comparing colchicine (0.5 mg twice daily for the first 3 days and then once daily for 27 days thereafter) with placebo in a 1:1 ratio (NCT04322682). Patients were eligible if they were at least 40 years of age, had received a diagnosis of COVID-19, were not hospitalised, and presented at least one of the following high-risk criteria: age of 70 years or more, obesity (body-mass index of 30 kg/m 2 or more), diabetes, uncontrolled hypertension (systolic blood pressure > 150 mm Hg), known respiratory disease, known heart failure, known coronary disease, fever of at least 38.4°C within the last 48 hours, dyspnea at the time of presentation, bicytopenia, pancytopenia, or the combination of high neutrophil and low lymphocyte counts. Main exclusion criteria included inflammatory bowel disease, chronic diarrhea, estimated glomerular filtration rate (eGFR) less than 30 ml/minute/1.73 m 2 , severe liver disease, current treatment with colchicine, or a history of significant sensitivity to colchicine. Clinical evaluation visits occurred by telephone at 15-and 30days following randomisation from March 2020 to January 2021.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) At the time of consent to the main COLCORONA study, 3315 participants were asked whether they could be recontacted to take part in the optional pharmacogenomic substudy. Those who agreed were called back by the team to obtain a separate consent for the genetic study and to plan for saliva sample collection. Exclusion details are shown in Supplementary Fig. 1 . There were 2441 participants recruited into the genetic study. Of the 2249 samples genotyped, 20 were excluded due to <98% genotyping completion rate, 3 samples with discordant sex between clinical and genetic data sets were excluded, one contaminated sample was removed, 16 geneticallydetermined related family members were excluded and we excluded 232 outliers from the cluster based on 1000 Genomes CEU reference samples (Utah Residents with Northern and Western European Ancestry) according to multidimensional scaling. One patient was excluded from the intent to treat population, 3 never received the study drug, and 142 patients who did not have a confirmatory COVID-19 diagnostic test were excluded, leaving 1855 patients for analysis. Written informed consent was obtained from all participants. The study was approved by the Montreal Heart Institute research ethics committee and complies with the Declaration of Helsinki.

The day of the end of COVID-19 symptoms was reported by the COLCORONA trial participants during the follow-up telephone visits that occurred on days 15 and 30 of the study. The event date was set as the study day of last known symptoms, alternatively patients were censored at the date of the patients' last telephone visit. Hospitalized participants were considered as having ongoing symptoms. There were 132 (7%) participants with missing or incomplete information on reported symptom dates, leaving 1723 participants for the analysis of time to symptom remission. The proportion of participants with missing information in the genetic substudy was comparable to the . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint proportion in the COLCORONA trial (359/4488; 8%). Further investigations for the 132 excluded participants found related research nurses' notes for 34 patients, 14 had reported symptom initiation after the baseline visit, and 20 had reported having no symptoms. Information on the dates of symptom occurrence was collected, but the specific symptoms themselves were not collected. No deaths were reported in participants to the genetic study, consequently the severity outcome was limited to hospitalisation for reasons of COVID-19 in the 30 days following randomisation.

DNA was obtained using the Oragene OG-500 self-collection saliva kits delivered to and collected from the participants' home while respecting distancing and quarantine restrictions. BeadChips were scanned using the Illumina iScan Reader and analysed with the data manifest MHI_GSAMD-24v3-0-EA_20034606_C2.bpm, with minor manual cluster adjustment for ADME genes. Plink files were produced by the iaap-cli tool (version 1.1.0-80d7e5b). Intensities, B allele frequency, and log R ratio were extracted using the gtc_convert tool (version 0.1.2). pyGenClean 10 version 1.8.3 and PLINK 11 version 1.07 or 1.9 were used to conduct quality control and genetic data clean-up processes. The genotyping experiment consisted of 28 plates of DNA samples with one Coriell control per hybridization experiment. The pairwise concordance of control samples ranged from 0.99998 to 0.999998 and concordance of their genotypes with expectation from the 1000 Genomes genotype data ranged from 0.9986 to 0.9989.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint

The completion rate threshold for genotypes and samples was set to 98%. SNPs with genotyping plate bias (n = 213) based on the 96 well plates used to dilute DNA samples were flagged but not removed as the effect of genetic ancestry could not be excluded. Pairwise identityby-state (IBS) was used to conduct close familial relationship checks. We removed all but one member of related samples based on a selection of uncorrelated SNPs (r 2 < 0.1). The pairwise IBS matrix was used as a distance metric to identify cryptic relatedness among samples and to identify cluster outliers by multidimensional scaling (MDS). The coordinates of the first two MDS components of each subject were plotted including the genotypes of HapMap CEU, JPT-CHB, and YRI data (unrelated individuals). Outliers from the main cluster overlapping the CEU reference samples (Utah residents with Northern and Western European ancestry from the CEPH collection)

were removed according to k-nearest neighbour with a threshold of 1.9σ in pyGenClean (v1.8.3).

Principal components were generated based on the final sample selection and used to control for confounding by ancestry in genetic association analyses. 12 Genome-wide imputation was performed on the TOPMed Imputation Server (version 1.5.7) 13 using Eagle (version 2.4) 14 for phasing and Minimac4 (version 1.0.2) 13 for imputation.

Following quality control, 513,036 genetic variants were used for imputation. The imputation provided 308,070,060 (513,036 genotyped and 307,557,024 imputed) genetic from which we retained 43,062,846 (513,012 genotyped and 42,549,834 imputed) variants with a quality value (r 2 ) ≥ 0.6, and of which 6,490,603 had a minor allele frequency (MAF) ≥ 5%. Genotype "hard calls" (non-probabilistic best-guess genotype assignations) were generated for individual genotypes with genotype probability scores ≥ 0.80 and otherwise set to missing. The hard calls were used only in analyses stratified by genotype. Chromosomal positions are according to GRCh38.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint

Genome-wide association analysis (GWAS) with common genetic variants (MAF ≥ 5%) were conducted using the program genetest version 0.5.0. 15 Cox proportional hazards regression was used for the GWAS of time from randomisation to end of COVID-19 symptoms (time to remission) in 1723 study participants. Logistic regression was used for the analysis of the severity endpoint of hospitalisation for COVID-19 in 1855 participants. To avoid bias due to population structure, analyses were limited to unrelated individuals of genetically determined European ancestry, which was the largest population group in the sample. Genetic variants were coded according to imputation dosage in (0 -2) and tested using a 1-degree of freedom Wald test adjusted for age, sex, and the first 10 principal components to control for genetic ancestry, with the addition of the study treatment arm when both arms were included in the analyses. GWAS were conducted using patients from both study arms, as well as stratified by treatment arms. Exploratory sexstratified analyses are reported in Supplementary Material. The GWAS for hospitalisation due to COVID-19 was only performed using both study arms due to the limited number of events.

Each GWAS was conducted at the 5 × 10 -8 significance level to adjust for the multiple testing of genetic variants within each phenotype. No additional adjustments were made to account for the multiple phenotypes or different statistical methods. Results are reported with point estimates and 95% confidence intervals (CI) which are not adjusted for multiple comparisons. The top findings from the GWAS were reproduced using SAS version 9.4. The proportionality of hazards assumption was verified for variants identified in a Cox proportional hazards regression GWAS, and the convergence criterion was met for each considered model. Cumulative incidence plots were obtained using a parametric model fitted with the R package. In order to quantify the effect . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. of the genetic variants upon the duration of symptoms, we fitted a Weibull accelerated failure time model adjusted for age, sex and 10 principal components using the lifereg procedure in SAS 9.4.

We first defined credible candidate variants as those located within 500 kb of the leading variants and with P values within two orders of magnitude of the lead variant. We used the software GCTA-CoLo 16 to conduct a conditional analysis to identify independent signals. We used PAINTOR 17 to identify credible sets of causal variants based on the magnitude and direction of association and the pairwise linkage disequilibrium structure at the loci, and we used RegulomeDB 18 and DSNetwork 19 to assign a relative ranking to variants. We used in silico functional annotations from the public databases Open Target Genetics 20 and PhenoScanner 21, 22 to identify potential functional mechanisms and target genes. We tested the colocalization between the COLCORONA GWAS signals and clinically relevant phenotypes using the COLOC R package v3.2-1. 23 Network analysis of selected candidate genes was conducted using GeneMANIA. 24 The complete approach is detailed in Supplementary Material.

The anonymized patient level data from the COLCORONA trial will be shared via the Vivli (vivli.org) data repository. The patient level genetic data underlying this article cannot be shared to preserve the privacy of study participants. Summary statistics from the GWAS results are available for download and visualisation via PheWeb 25 at statgen.org/pheweb/colcorona.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

There were 1855 participants available for the genetic study of COLCORONA ( Supplementary   Fig. 1) . The baseline characteristics of the participants to the genetic study are shown in Table 1 .

The mean age of participants was 54.1 years, 56.2% were female, mean BMI was 30.2 kg/m 2 , 16.3% had a medical history of diabetes, 32.1% of hypertension, and 29.4% of respiratory disease.

There were 1254 (72.8%) participants who reported being free of COVID-19 symptoms during the study follow-up period, and the mean number of days between randomisation and end of COVID-19 symptoms in those participants was 11.7 days. Mean number of days between first symptoms and randomisation was 5.4 days ( Table 1) . Overall, women reported longer symptom duration than men (Supplementary Table 1 ). The COLCORONA primary endpoint of death or hospitalisation for COVID-19 differed significantly between the full trial population and the genetic substudy. Whereas there were 14 (0.3%) reported deaths in the COLCORONA trial, none of the participants to the genetic study died (P < 0.001), and there were 229 (5.1%) hospitalisation for COVID-19 in the trial compared to 58 (3.1%) in the genetic study (P < 0.001).

There were 1723 participants included in the GWAS for time to remission of COVID-19 symptoms. Of those, 1254 (72.8%) reported end of symptoms during the study period and 469 were censored at the date of their last telephone visit. We found two candidate genomic regions significantly associated with time to symptom remission located on chromosomes 5 and 9 ( Fig.   1 ). Sex-stratified GWAS did not find additional associations (Supplementary Material). We found one significant association signal in the GWAS for time to COVID-19 symptom remission using both study arms at the 5p13.3 locus with the leading variant rs1173773 (P = 4.94 × 10 -8 ;

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint MAF 0.34). When conditioning on rs1173773, no additional genetic variants remained significant at P <5 × 10 -8 in the region and rs1173773 had the highest probability of being causal according to statistical and functional prioritization. The minor allele (C) was associated with a higher remission rate (hazard ratio (HR) = 1.25, 95% CI 1.15-1.35) as compared to the T allele, irrespective of treatment arm (interaction P = 0.18) ( Table 2) . According to survival modeling, 44%, 54% and 59% of patients with the TT, CT and CC genotypes respectively were predicted to have had symptom remission by day 15 of the study (Fig. 2, Table 3 ). Using an accelerated failure time model, we calculated that the C allele contributes to symptom remission with an acceleration factor of 0.84 (95% CI 0.80-0.89) compared to the T allele (P = 5.23 × 10 -9 ). Compared to patients with the rs1173773-TT genotype, patients with the CC genotype had symptom remission with an acceleration factor of 0.73 (95% CI 0.64-0.82; P = 3.89 × 10 -7 ), and the CT genotype had an acceleration factor of 0.82 (95% CI 0.75-0.89; P = 6.30 × 10 -6 ). The rs1173773 variant is located in intron 3 of the most abundant transcript of the natriuretic peptide receptor 3 gene (NPR3).

However, functional analysis found no evidence supporting a regulatory role for this variant. The rs1173773 C allele that is associated with shorter duration of COVID-19 symptoms was previously found to be associated with greater standing height, 26 and variants in NPR3 have also been associated with forced expiratory volume in 1 second (FEV1), 26 and systolic blood pressure. 27

The most significant association in the GWAS for time to remission of COVID-19 symptoms in the 851 participants from the placebo arm was at 9q33.1 with the intergenic variant rs62575331 (P = 2.95 × 10 -8 , MAF = 0.12). When conditioning on rs62575331, no additional genetic variants remained significant at P <5 × 10 -8 in the region and rs62575331 had the highest probability of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint being causal according to statistical and functional prioritization. The minor allele (G) at the rs62575331 variant leading the 9q33.1 signal was associated with symptom remission (HR=1.57, 95% CI 1.34-1.84). The association of the variant with symptom remission in the colchicine arm was not significant (P = 0.15) and the interaction between the variant and colchicine treatment was significant (P = 1.19 × 10 -5 ), highlighting a possible interaction with colchicine on symptoms duration that may be due to a shared biological pathway between the genetic variant and colchicine ( Table 2) . We calculated that 46%, 62% and 64% of those in the placebo-group with the CC, CG and CG genotypes respectively had symptom remission by day 15 of the study (Fig. 2, Table 3 ).

In accelerated failure time modeling, compared to the C allele, the G allele contributed to symptom remission with an acceleration factor of 0.71 (95% CI 0.64-0.80; P = 4.83 × 10 -9 ). Patients with the rs62575331-GG genotype had symptom remission with an acceleration factor of 0.52 (95% CI 0.36-0.75; P = 5.24 × 10 -4 ), and patients with the CG genotype an acceleration factor of 0.71 (95% CI 0.61-0.82; P = 2.09 × 10 -6 ) as compared to the CC genotype. Functional analysis found rs62575331 to be an eQTL of the lncRNA AL355601.1 (GTEx v7; P = 1.1 × 10 -18 ) 28 , which was found to colocalize with a GWAS of varicose veins. 20, 29 The rs62575331-C allele was associated with height (P = 2.3 × 10 -5 ), similarly to variants in the pappalysin 1 gene (PAPPA) (P < 1 × 10 -45 ) 22 ,26,30 which is the nearest coding gene by transcriptional start site to the leading variant rs62575331. The second-best GWAS signal in the GWAS with the placebo group did not reach statistical significance but was at locus 5p13.3, which was concordant to the region found by GWAS with participants from both study arms. The rs62575331 variant was not associated with the risk of hospitalisation for COVID-19 in the placebo arm (P = 0.87) or in the colchicine arm (P = 0.61) and had no interaction effect with colchicine on hospitalisation risk.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint

We conducted a GWAS for hospitalisation due to COVID-19 which occurred in 58 (3.1%) of the 1855 subjects included in the analysis. The study had limited power (Supplementary Methods) and none of the tested genetic variants passed the GWAS significance threshold (P < 5×10 -8 ) (Supplementary Fig. 2 ).

We report the results of a genome-wide association study of time to remission of COVID-19 symptoms in an outpatient population recently diagnosed with COVID-19 and who presented with at least one risk factor for COVID-19 complications. We found two genomic regions associated with symptom remission located at 5p13.3 and 9q33.1. The 5p13.3 locus spans the NPR3 gene, encoding a receptor for the binding of the natriuretic peptides which is involved in the clearance of natriuretic peptides, diuresis, blood pressure, and cardiometabolic diseases. 31 NPR3 is involved in the extended renin-angiotensin system which has been proposed as a possible mechanisms involved in the development of lung injury in COVID- 19. 32 The allele associated with remission of COVID-19 symptoms at the chromosome 5 locus has previously been associated with height, 26 and variants in NPR3 have also been associated with forced expiratory volume in 1 second (FEV1), 26 and systolic blood pressure. 27 The allele associated with symptom remission at the leading variant at 9q33.1 was also previously associated with greater standing height 26 . The variant is an eQTL of a neighbouring lncRNA increasing the risk of venous abnormalities. 20, 29 The chromosome 9 locus variant had a genetic effect on symptom remission which was limited to participants in the placebo arm, and it is possible that the pharmacological effects of colchicine. In the COLCORONA trial, colchicine was not found to modulate duration of COVID-19 symptoms.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint It is possible that the genetic variant at 9q33.1 may act in a biological pathway that is shared with that of colchicine, which acts on multiple inflammatory pathways including the NLRP3 inflammasome. 33,34 A recent report by Stella and colleagues 35 on familial Mediterranean Fever (FMF) in the context of COVID-19 argues that there could be a finely regulated competition between the NLRP3 inflammasome and pyrin that is necessary to maintain protective inflammation levels. FMF is an inherited monogenic autoinflammatory disorder caused by excess activity of the pyrin protein and which is typically treated with colchicine to prevent fever attacks. for COVID-19 had symptoms that lasted for 5 weeks or longer, and one in ten had symptoms that . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint lasted for 12 weeks or longer. 2 Whether the genetic variants identified in the present study represent risk factors for such long COVID-19 symptoms remains to be verified.

Our study had some limitations. Notably, we had limited power to study the more severe outcomes of death or hospitalisation for COVID-19 due in part to a healthy volunteer bias. The invitation and consent to the genetic substudy occurred after the randomisation visit, and very ill patients may have been less likely to agree to the additional interview or may have already died or been hospitalised by the time of recontact. We made all efforts to rapidly reach all participants and persisted recontact attempts even after the end of the 30-day follow-up period on treatment.

Healthy volunteer bias is frequent in optional pharmacogenomic studies of clinical trials. To diminish this bias, a simultaneous consent process with the main study and the collection of genetic material at the randomisation visit is recommended. In practice, however, the additional consent for the genetic study adds time to the recruitment process and can be a deterrent to overall participation, particularly for a disease with acute onset such as COVID-19. Information on symptom types was not collected in this study. Because analyses were conducted with individuals of European genetic ancestry, validation of the genetic associations in other populations will be necessary. Importantly, the results have not yet been replicated in an independent population sample, and we cannot exclude the possibility that the results may be chance findings.

This is the first study to report a GWAS for time to remission of symptoms in non-hospitalized patients with COVID-19 with at least one risk factor for a severe form of the disease. We found two genomic regions associated with symptom remission located at 5p13.3 and 9q33. in . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint

a. Using a Cox proportional hazards regression with 1723 subjects from the colchicine and placebo arms of the COLCORONA study, controlling for study arm, sex, age, and 10 principal components for genetic ancestry, with 6,392,715 genetic variants of minor allele frequency ≥ 5%.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint b. Using a Cox proportional hazards regression with 851 subjects from the placebo arm of the COLCORONA study, controlling for sex, age, and 10 principal components for genetic ancestry, with 6,390,776 genetic variants of minor allele frequency ≥ 5%.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint percutaneous coronary intervention; SD: standard deviation . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 1, 2021. ; https://doi.org/10.1101/2021.02.24.21252396 doi: medRxiv preprint 0.81 ---Cumulative incidence estimates were derived from Cox proportional hazards using genotype hard calls with adjustment for age, sex, 10 principal components, and for the analysis of rs1173773, with additional adjustment for study arm. Remission proportion was calculated as 1-symptom persistence probability. Chr: chromosome.

Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States

The prevalence of long COVID symptoms and COVID-19 complications

A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection

Genetic mechanisms of critical illness in Covid-19

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility

The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic

Reference-based phasing using the Haplotype Reference Consortium panel

GCTA: a tool for genome-wide complex trait analysis

Improved methods for multi-trait fine mapping of pleiotropic risk loci

Annotation of functional variation in personal genomes using RegulomeDB

DSNetwork: An Integrative Approach to Visualize Predictions of Variants' Deleteriousness

Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics

PhenoScanner V2: an expanded tool for searching human genotypephenotype associations

PhenoScanner: a database of human genotype-phenotype associations

Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses

The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function

Exploring and visualizing large-scale genetic associations by

Reported results are for Cox proportional hazards regression adjusted for age, sex, and 10 principal components for genetic ancestry; and for the analysis of rs1173773, with additional adjustment for study arm. Interaction P value for the variant by colchicine interaction term